Technology

Champions Oncology

$11.64
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.24 (+2.11%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell CSBR and other stocks, options, and ETFs commission-free!

About CSBR

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ. The listed name for CSBR is Champions Oncology, Inc. Common Stock.

CEO
Ronnie Morris
Employees
143
Headquarters
Hackensack, New Jersey
Founded
1985
Market Cap
153.84M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
18.05K
High Today
$11.74
Low Today
$11.23
Open Price
$11.37
Volume
22.02K
52 Week High
$13.45
52 Week Low
$4.02

Collections

CSBR Earnings

-$0.14
-$0.08
-$0.02
$0.04
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
— per share
Actual
Expected Mar 11, After Hours

You May Also Like

IVA
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure